said Thursday it will pull the medicine from the market, acknowledging it didn't help patients with the deadly neurological condition.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS," company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.Amylyx also said Thursday it will lay off 70% of its more than 350 employees as part of a major restructuring effort.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why Amylyx is pulling ALS drug Relyvrio from US market after studyThe maker of a drug for Lou Gehrig’s disease that recently failed in a study says it will pull the medicine from the U.S. market. Amylyx Pharmaceuticals said Thursday it will halt marketing in the U.S. and Canada. In March, the drugmaker announced that its drug had failed to show any benefit for patients in a 600-person study.
Source: AP - 🏆 728. / 51 Read more »
Amylyx Pharmaceuticals to Remove ALS Drug from MarketAmylyx Pharmaceuticals has announced that it will voluntarily remove its drug for amyotrophic lateral sclerosis (ALS) from the market. This decision comes after a recent clinical trial showed that the treatment is ineffective.
Source: washingtonpost - 🏆 95. / 72 Read more »
Amylyx Pharmaceuticals to Pull Drug for Lou Gehrig’s Disease from MarketAmylyx said last month it was considering pulling its drug Relyvrio after a clinical trial in 600 patients failed to show any improvements in survival or other health measures. The maker of the drug has now announced that it will voluntarily halt sales and marketing of the drug, acknowledging its lack of effectiveness in helping patients with the deadly neurological condition.
Source: nbcsandiego - 🏆 524. / 51 Read more »